Advertisement
PFE vs XLV
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PFE is a StrongBuy and XLV is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PFE’s FA Score shows that 2 FA rating(s) are green while.
- PFE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PFE’s TA Score shows that 5 TA indicator(s) are bullish.
- PFE’s TA Score: 5 bullish, 5 bearish.
Price Growth
PFE (@Pharmaceuticals: Major) experienced а +15.19% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +4.59%. For the same industry, the average monthly price growth was +2.98%, and the average quarterly price growth was +21.92%.
Reported Earning Dates
PFE is expected to report earnings on Nov 04, 2025.
Industries' Descriptions
@Pharmaceuticals: Major (+4.59% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
PFE | ||
|---|---|---|
OUTLOOK RATING 1..100 | 29 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | |
PROFIT vs RISK RATING 1..100 | 97 | |
SMR RATING 1..100 | 62 | |
PRICE GROWTH RATING 1..100 | 22 | |
P/E GROWTH RATING 1..100 | 98 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| PFE | XLV | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 57% | 3 days ago 77% |
| Stochastic ODDS (%) | 3 days ago 49% | 3 days ago 68% |
| Momentum ODDS (%) | 3 days ago 46% | 3 days ago 74% |
| MACD ODDS (%) | 3 days ago 48% | 3 days ago 80% |
| TrendWeek ODDS (%) | 3 days ago 57% | 3 days ago 82% |
| TrendMonth ODDS (%) | 3 days ago 52% | 3 days ago 84% |
| Advances ODDS (%) | 5 days ago 57% | 5 days ago 82% |
| Declines ODDS (%) | 11 days ago 60% | 11 days ago 82% |
| BollingerBands ODDS (%) | 3 days ago 53% | 3 days ago 75% |
| Aroon ODDS (%) | 3 days ago 58% | 3 days ago 82% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FNDF | 43.73 | 0.41 | +0.95% |
| Schwab Fundamental International Eq ETF | |||
| NBSM | 25.66 | 0.16 | +0.63% |
| Neuberger Berman Small-Mid Cap ETF | |||
| AUSF | 46.56 | 0.20 | +0.43% |
| Global X Adaptive US Factor ETF | |||
| OCTM | 32.21 | 0.01 | +0.03% |
| FT Vest U.S. Equity Max Buffer ETF – Oct | |||
| THTA | 15.13 | -0.02 | -0.12% |
| SoFi Enhanced Yield ETF | |||
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with GSK. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then GSK could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | +1.07% | ||
| GSK - PFE | 61% Loosely correlated | -0.78% | ||
| NVS - PFE | 60% Loosely correlated | +1.08% | ||
| BIIB - PFE | 59% Loosely correlated | +2.98% | ||
| BMY - PFE | 57% Loosely correlated | +0.75% | ||
| ABBV - PFE | 56% Loosely correlated | -1.12% | ||
More | ||||
XLV and
Correlation & Price change
A.I.dvisor indicates that over the last year, XLV has been closely correlated with TMO. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if XLV jumps, then TMO could also see price increases.